ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103

Its studies are mostly in Neoplasm Metastasis, led by Avenzo Therapeutics.

Furthest: phase 2, since Sep 24, 20251 company-led study, 1 open or runningNext primary completion: Mar 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Avenzo Therapeutics11 open or runningphase 2since Sep 24, 2025Sep 24, 2025Mar 2030phase 2 · NCT07193511

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 24, 2025First study: phase 2 study in Neoplasm MetastasisFirst studyNCT07193511 · 355 planned · United States

Ahead

  1. Mar 2030Primary completion: phase 2 study in Neoplasm MetastasisNCT07193511

TargetBeta

“An antibody-drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) nectin-4 (PVRL4) and trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07193511Neoplasm Metastasis · United States2RecruitingMar 2030355

How it is read

Names in the registry

  • “AVZO-103”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.